<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00802880</url>
  </required_header>
  <id_info>
    <org_study_id>08-1299 / 201109179</org_study_id>
    <nct_id>NCT00802880</nct_id>
  </id_info>
  <brief_title>Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma</brief_title>
  <official_title>Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the overall best tumor response rate to dacarbazine
      given until disease progression as assessed by RECIST criteria, CT and clinical exams in
      patients with metastatic sarcomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The two reasons why dacarbazine was eliminated from treatment options for patients with
      metastatic sarcoma included inability to effectively address the drug's major toxicities
      (emesis and neutropenia) and the prevailing opinion that the drug was less effective than
      other chemotherapeutic agents.

      Specific Aim #1: The primary endpoint of this study is to determine the overall best tumor
      anatomic response rate (CR- complete response, PR - partial response, SD - stable disease, or
      PD - progressive disease) to dacarbazine given until disease progression as assessed by
      RECIST criteria using CT and clinical examination in patients with metastatic sarcoma.

      The prevailing opinion that dacarbazine was less effective than other chemotherapeutic agents
      in this setting was not based on data from controlled randomized clinical trials. Indeed, we
      are not aware of a single randomized trial that was conducted and reported which compared the
      anti-tumor activity of single agent dacarbazine to that of other active single agents in this
      patient population. However, phase two trials clearly established that dacarbazine had
      anti-tumor activity in the treatment of metastatic sarcoma, and our personal experience at
      this institution has confirmed that this is true. In addition, randomized trials demonstrated
      that the addition of dacarbazine to doxorubicin increased tumor response rates over
      doxorubicin alone.12 The literature supports the conclusion that dacarbazine has anti-tumor
      activity in the treatment of metastatic sarcoma.

      Historically, in most studies, tumor response to dacarbazine was assessed by WHO criteria.
      However, current assessment of tumor response usually is based on RECIST criteria, which
      differ from the WHO criteria, as shown:

      Studies have not been performed to determine the tumor anatomic response rate of single agent
      dacarbazine using RECIST criteria. This study will determine the tumor anatomic response rate
      as assessed by RECIST criteria to dacarbazine in patients with metastatic sarcoma. Modern
      methods of CT scans will be used to assess tumor response which contrasts with the earlier
      methods to assess tumor response to dacarbazine used in most of the published reports. These
      methods included physical examination and conventional X-ray or first generation, lower
      resolution CT scans. The current methods of radiologic assessment of tumor response are
      superior to those used over 15 years ago. The latest generation of CT scans more accurately
      measure and image a tumor mass, which may better assess tumor response to therapy.

      Specific Aim #2: To determine the overall risk of nausea/emesis (any grade) and neutropenia
      (grade 3 or 4) with dacarbazine when given with current antiemetic agents
      (5-hydroxytryptamine-3 serotonin antagonist, dexamethasone, and aprepitant) and with
      pegfilgrastim.

      Historically, dacarbazine-induced toxicities such as emesis and myelosuppression were common
      and led to significant dose reductions and delays which could have negatively impacted the
      drug's anti-tumor activity. When dacarbazine was initially identified as a potentially
      effective agent for the treatment of sarcoma, the anti-emetic drugs available had limited
      efficacy. Also, there were no measures available to prevent chemotherapy-induced neutropenia.
      Today, there are very effective drugs that can prevent and reduce the frequency of both
      chemotherapy-induced emesis and neutropenia.

      Dacarbazine carries the risk of emesis (all grades) of &gt;90% of cases when administered
      without antiemetics13. A three-drug anti-emetic combination of a 5-hydroxytryptamine-3
      serotonin antagonist, dexamethasone, and aprepitant is the current recommendation from ASCO
      when administering highly emetogenic chemotherapy drugs13. Hesketh, et al reported that the
      risk of emesis (all grades) following highly emetogenic chemotherapy (cisplatin) and
      pre-medication with this three drug anti-emetic regimen was 27% compared to a two drug
      regimen of ondansetron and dexamethasone in which the risk was 48% (p&lt; 0.001)14.

      Prior studies showed that the risk of grade 3 or 4 neutropenia following dacarbazine given
      without granulocyte- colony stimulating factors was 36%15. Granulocyte- colony stimulating
      factors (pegfilgrastim or neupogen) are effective agents in preventing chemotherapy-induced
      neutropenia. Crawford, et al showed in a randomized trial that risk of chemotherapy- induced
      grade four neutropenia was one day with G-CSF compared to six days with placebo15. Subsequent
      randomized trials showed equivalent efficacy of pegfilgrastim compared with neupogen16.
      Vogel, et al reported in a phase three double blinded randomized trial of patients with
      breast cancer receiving docetaxel 100 mg/m2 that pegfilgrastim compared to placebo reduced
      the incidence of febrile neutropenia ( 1% vs 17%, p&lt; 0.001) and febrile neutropenia-related
      hospitalization (1% vs 14%, p&lt; 0.001)17.

      In this trial, we hypothesize that the implementation of these newer anti-nausea agents
      (5-hydroxytryptamine-3 serotonin antagonist, dexamethasone, and aprepitant) and
      granulocyte-colony stimulating factor (pegfilgrastim) as a primary prophylactic strategy will
      reduce the frequency of dacarbazine-induced nausea/emesis (any grade) and neutropenia (grade
      3 or 4).

      Specific Aim #3: To compare the SUV at up to three target tumor sites and to determine the
      overall tumor metabolic response (complete metabolic response, partial metabolic response,
      stable metabolic disease or progressive metabolic disease (CMR, PMR, SMD, or PMD) as assessed
      by FDG-PET/CT performed at baseline and then after every three cycles of treatment with
      dacarbazine.

      Studies have not been performed to determine the changes in FDG uptake by PET imaging
      following dacarbazine in patients with metastatic sarcoma. There is limited published data
      about changes in FDG uptake by PET imaging following other chemotherapy agents in patients
      with metastatic sarcoma. However, there is an emerging body of data showing the prognostic
      impact of early tumor response to targeted agents (imatinib or sunitinib) as assessed by
      FDG-PET in patients with metastatic GIST18. In this trial, we will determine the tumor
      metabolic response to dacarbazine as assessed by FDG-PET/CT and correlate this to the tumor
      anatomic response as assessed by CT scans.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Anatomical Tumor Response</measure>
    <time_frame>After completion of 3 cycles</time_frame>
    <description>Complete response (CR): disappearance of all target lesions, disappearance of all non-target lesions, normalization of tumor level marker
Partial response (PR): at least 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD, persistence of one or more non-target lesion and/or maintenance of tumor marker level above the upper limits of normal
Stable disease (SD): neither sufficient shrinkage in target lesions to qualify for PR nor sufficient increase to qualify for progressive disease taking as references the smallest sum LD since the treatment started, persistence of one or more non-target lesion and/or maintenance of tumor marker level above the normal limits of normal
Progressive disease (PD): at least 20% increase in the sum of the LD of target lesions and/or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Neutropenia (Grade 3/4)</measure>
    <time_frame>Completion of 6 cycles of treatment (18 weeks)</time_frame>
    <description>Grade 3 neutropenia = absolute neutrophil count of &lt;1000 - 500/mm^3
Grade 4 neutropenia = absolute neutrophil count of &lt;500/mm^3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Nausea/Emesis (Any Grade)</measure>
    <time_frame>Completion of 6 cycles of treatment (18 weeks)</time_frame>
    <description>Approximately 18 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the SUV at up to 3 Tumor Sites</measure>
    <time_frame>Baseline and after every three cycles of treatment (up to 1 year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Tumor Metabolic Response</measure>
    <time_frame>After completion of 3 cycles</time_frame>
    <description>Complete metabolic response (CMR)-complete resolution of all metabolically active target and non-target lesions, and no interval development of new lesions.
Partial metabolic response (PMR)
Target lesions: 20% or greater decrease in maximum SUV from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions.
Non-target lesions: decrease in total number of non-target lesions, without complete resolution of metabolically active disease, or unequivocal decrease in degree of FDG activity within &gt;50% of the lesions. No unequivocal new lesions.
Stable metabolic disease (SMD): does not qualify for CMR, PMR, or PMD.
Progressive metabolic disease (PMD):
Unequivocal development of one more new metabolically active lesions
Target lesion: 20% or greater increase in maximum SUV from baseline.
Non-target lesions: unequivocal increase in FDG activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate the Tumor Metabolic Response Rate With the Tumor Anatomic Response Rate</measure>
    <time_frame>After completion of 3 cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Disease Control Rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Until completion of follow-up (estimated to be 1 year)</time_frame>
    <description>-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Until completion of follow-up or patient death (estimated to be 1 year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate the Time to Progression With Best Anatomic Response</measure>
    <time_frame>Completion of follow-up (estimated to be 1 year)</time_frame>
    <description>-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate Time to Progression With Best Metabolic Response</measure>
    <time_frame>Completion of follow-up (estimated to be 1 year)</time_frame>
    <description>-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate Overall Survival With Best Anatomic Response</measure>
    <time_frame>Completion of follow-up (estimated to be 1 year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate Overall Survival With Best Metabolic Response</measure>
    <time_frame>Completion of follow-up (estimated to be 1 year)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Dacarbazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dacarbazine 850 mg/m^2 IV Day 1 of each 21 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <arm_group_label>Dacarbazine</arm_group_label>
    <other_name>DTIC</other_name>
    <other_name>DTIC-Dome</other_name>
    <other_name>DIC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven diagnosis of soft tissue or bone sarcoma

          -  Metastatic or locally recurrent and unresectable sarcoma which progressed after one or
             more prior chemotherapy regimens (excluding adjuvant chemotherapy).

          -  At least one measurable tumor lesion (by CT scan) At least one FDG avid (SUV ≥ 3)
             tumor lesion (by PET/CT) which must have been performed at this institution. At least
             one of these target lesions must be ≥ 1.5 cm in smallest dimension as measured on the
             baseline CT

          -  Age greater than 18 yrs old

          -  ECOG Performance Status of 0-2

          -  Baseline ANC ≥ 1000/uL, Hgb ≥ 8 Gr/dL, platelets ≥ 100,000/ dL.

          -  Baseline serum creatinine &lt;/= 2.0 mg/dL

          -  Baseline serum total bilirubin &lt;/= 2.0, AST or ALT &lt; 3x ULN

          -  No active infection

          -  Signed Informed Consent by patient or legally authorized representative

        Exclusion Criteria:

          -  Current pregnancy or breast feeding.

          -  A serious uncontrolled medical disorder that in the opinion of the Investigator would
             impair the ability of the subject to receive protocol therapy.

          -  Chemotherapy, radiation therapy, or investigational agents given with the last 21
             days.

          -  Investigational agents given with the last 30 days

          -  Uncontrolled diabetes mellitus. (Subjects with a fasting blood glucose &gt; 200 at time
             of PET scanning may need to reschedule to another day after consulting with
             appropriate physicians.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Van Tine, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington Univerisity School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <reference>
    <citation>Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993 Jul;11(7):1276-85.</citation>
    <PMID>8315425</PMID>
  </reference>
  <reference>
    <citation>Gottlieb JA, Benjamin RS, Baker LH, O'Bryan RM, Sinkovics JG, Hoogstraten B, Quagliana JM, Rivkin SE, Bodey GP Sr, Rodriguez V, Blumenschein GR, Saiki JH, Coltman C Jr, Burgess MA, Sullivan P, Thigpen T, Bottomley R, Balcerzak S, Moon TE. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep. 1976 Feb;60(2):199-203.</citation>
    <PMID>769974</PMID>
  </reference>
  <reference>
    <citation>Buesa JM, Mouridsen HT, van Oosterom AT, Verweij J, Wagener T, Steward W, Poveda A, Vestlev PM, Thomas D, Sylvester R. High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group. Ann Oncol. 1991 Apr;2(4):307-9.</citation>
    <PMID>1868027</PMID>
  </reference>
  <reference>
    <citation>Borden EC, Amato DA, Rosenbaum C, Enterline HT, Shiraki MJ, Creech RH, Lerner HJ, Carbone PP. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol. 1987 Jun;5(6):840-50.</citation>
    <PMID>3585441</PMID>
  </reference>
  <reference>
    <citation>Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007 May 1;25(13):1753-9.</citation>
    <PMID>17470865</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <results_first_submitted>June 16, 2016</results_first_submitted>
  <results_first_submitted_qc>December 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 13, 2017</results_first_posted>
  <last_update_submitted>December 20, 2016</last_update_submitted>
  <last_update_submitted_qc>December 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study opened to accrual on 03/16/2009 and closed to accrual on 12/15/2014.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dacarbazine</title>
          <description>Dacarbazine 850 mg/m^2 IV Day 1 of each 21 day cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dacarbazine</title>
          <description>Dacarbazine 850 mg/m^2 IV Day 1 of each 21 day cycle.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="20" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Best Anatomical Tumor Response</title>
        <description>Complete response (CR): disappearance of all target lesions, disappearance of all non-target lesions, normalization of tumor level marker
Partial response (PR): at least 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD, persistence of one or more non-target lesion and/or maintenance of tumor marker level above the upper limits of normal
Stable disease (SD): neither sufficient shrinkage in target lesions to qualify for PR nor sufficient increase to qualify for progressive disease taking as references the smallest sum LD since the treatment started, persistence of one or more non-target lesion and/or maintenance of tumor marker level above the normal limits of normal
Progressive disease (PD): at least 20% increase in the sum of the LD of target lesions and/or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions</description>
        <time_frame>After completion of 3 cycles</time_frame>
        <population>3 patients failed to complete 3 cycles of treatment due to toxicity. 22 patients failed to complete 3 cycles of treatment due to progressive disease. 1 patient only had PET scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Dacarbazine</title>
            <description>Dacarbazine 850 mg/m^2 IV Day 1 of each 21 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Best Anatomical Tumor Response</title>
          <description>Complete response (CR): disappearance of all target lesions, disappearance of all non-target lesions, normalization of tumor level marker
Partial response (PR): at least 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD, persistence of one or more non-target lesion and/or maintenance of tumor marker level above the upper limits of normal
Stable disease (SD): neither sufficient shrinkage in target lesions to qualify for PR nor sufficient increase to qualify for progressive disease taking as references the smallest sum LD since the treatment started, persistence of one or more non-target lesion and/or maintenance of tumor marker level above the normal limits of normal
Progressive disease (PD): at least 20% increase in the sum of the LD of target lesions and/or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions</description>
          <population>3 patients failed to complete 3 cycles of treatment due to toxicity. 22 patients failed to complete 3 cycles of treatment due to progressive disease. 1 patient only had PET scan.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Neutropenia (Grade 3/4)</title>
        <description>Grade 3 neutropenia = absolute neutrophil count of &lt;1000 – 500/mm^3
Grade 4 neutropenia = absolute neutrophil count of &lt;500/mm^3</description>
        <time_frame>Completion of 6 cycles of treatment (18 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dacarbazine</title>
            <description>Dacarbazine 850 mg/m^2 IV Day 1 of each 21 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Neutropenia (Grade 3/4)</title>
          <description>Grade 3 neutropenia = absolute neutrophil count of &lt;1000 – 500/mm^3
Grade 4 neutropenia = absolute neutrophil count of &lt;500/mm^3</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Nausea/Emesis (Any Grade)</title>
        <description>Approximately 18 weeks</description>
        <time_frame>Completion of 6 cycles of treatment (18 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dacarbazine</title>
            <description>Dacarbazine 850 mg/m^2 IV Day 1 of each 21 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Nausea/Emesis (Any Grade)</title>
          <description>Approximately 18 weeks</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of the SUV at up to 3 Tumor Sites</title>
        <time_frame>Baseline and after every three cycles of treatment (up to 1 year)</time_frame>
        <population>The lower confidence limit is 85% and the upper confidence limit is 95%. 51 patients evaluable at baseline, 50 patients evaluable at end of cycle 3, 20 patients evaluable at end of cycle 6, 7 patients evaluable at end of cycle 9, and 5 patients evaluable at end of cycle 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Dacarbazine</title>
            <description>Dacarbazine 850 mg/m^2 IV Day 1 of each 21 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of the SUV at up to 3 Tumor Sites</title>
          <population>The lower confidence limit is 85% and the upper confidence limit is 95%. 51 patients evaluable at baseline, 50 patients evaluable at end of cycle 3, 20 patients evaluable at end of cycle 6, 7 patients evaluable at end of cycle 9, and 5 patients evaluable at end of cycle 12.</population>
          <units>standard uptake value</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.42" lower_limit="6.2" upper_limit="8.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of cycle 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.57" lower_limit="6.34" upper_limit="9.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of cycle 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="6.33" upper_limit="9.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of cycle 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.89" lower_limit="5.39" upper_limit="8.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of cycle 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.48" lower_limit="5.68" upper_limit="9.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Tumor Metabolic Response</title>
        <description>Complete metabolic response (CMR)-complete resolution of all metabolically active target and non-target lesions, and no interval development of new lesions.
Partial metabolic response (PMR)
Target lesions: 20% or greater decrease in maximum SUV from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions.
Non-target lesions: decrease in total number of non-target lesions, without complete resolution of metabolically active disease, or unequivocal decrease in degree of FDG activity within &gt;50% of the lesions. No unequivocal new lesions.
Stable metabolic disease (SMD): does not qualify for CMR, PMR, or PMD.
Progressive metabolic disease (PMD):
Unequivocal development of one more new metabolically active lesions
Target lesion: 20% or greater increase in maximum SUV from baseline.
Non-target lesions: unequivocal increase in FDG activity</description>
        <time_frame>After completion of 3 cycles</time_frame>
        <population>29 patients were not evaluable due to various reasons such as toxicity, progressive disease prior to completion of cycle 3, patient refusal, and no target lesions on PET scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Dacarbazine</title>
            <description>Dacarbazine 850 mg/m^2 IV Day 1 of each 21 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Tumor Metabolic Response</title>
          <description>Complete metabolic response (CMR)-complete resolution of all metabolically active target and non-target lesions, and no interval development of new lesions.
Partial metabolic response (PMR)
Target lesions: 20% or greater decrease in maximum SUV from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions.
Non-target lesions: decrease in total number of non-target lesions, without complete resolution of metabolically active disease, or unequivocal decrease in degree of FDG activity within &gt;50% of the lesions. No unequivocal new lesions.
Stable metabolic disease (SMD): does not qualify for CMR, PMR, or PMD.
Progressive metabolic disease (PMD):
Unequivocal development of one more new metabolically active lesions
Target lesion: 20% or greater increase in maximum SUV from baseline.
Non-target lesions: unequivocal increase in FDG activity</description>
          <population>29 patients were not evaluable due to various reasons such as toxicity, progressive disease prior to completion of cycle 3, patient refusal, and no target lesions on PET scan.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CMR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlate the Tumor Metabolic Response Rate With the Tumor Anatomic Response Rate</title>
        <time_frame>After completion of 3 cycles</time_frame>
        <population>31 patients were not evaluable due to various reasons such as toxicity, progressive disease prior to completion of cycle 3, patient refusal, and no target lesions on PET scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Partial Metabolic Response</title>
          </group>
          <group group_id="O2">
            <title>Stable Metabolic Disease</title>
          </group>
          <group group_id="O3">
            <title>Progressive Metabolic Disease</title>
          </group>
          <group group_id="O4">
            <title>Total</title>
          </group>
        </group_list>
        <measure>
          <title>Correlate the Tumor Metabolic Response Rate With the Tumor Anatomic Response Rate</title>
          <population>31 patients were not evaluable due to various reasons such as toxicity, progressive disease prior to completion of cycle 3, patient refusal, and no target lesions on PET scan.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Disease Control Rate</title>
        <time_frame>12 months</time_frame>
        <population>Only 6 patients were evaluable for response at the end of 12 cycles.</population>
        <group_list>
          <group group_id="O1">
            <title>Dacarbazine</title>
            <description>Dacarbazine 850 mg/m^2 IV Day 1 of each 21 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Disease Control Rate</title>
          <population>Only 6 patients were evaluable for response at the end of 12 cycles.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression (TTP)</title>
        <description>-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
        <time_frame>Until completion of follow-up (estimated to be 1 year)</time_frame>
        <population>10 patient observations with invalid time or censoring values were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Dacarbazine</title>
            <description>Dacarbazine 850 mg/m^2 IV Day 1 of each 21 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (TTP)</title>
          <description>-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
          <population>10 patient observations with invalid time or censoring values were not included.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" lower_limit="1.84" upper_limit="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>Until completion of follow-up or patient death (estimated to be 1 year)</time_frame>
        <population>One patient with invalid time or censoring value was not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Dacarbazine</title>
            <description>Dacarbazine 850 mg/m^2 IV Day 1 of each 21 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <population>One patient with invalid time or censoring value was not included.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.09" lower_limit="5.56" upper_limit="9.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlate the Time to Progression With Best Anatomic Response</title>
        <description>-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
        <time_frame>Completion of follow-up (estimated to be 1 year)</time_frame>
        <population>29 patients were not evaluable due to various reasons such as toxicity, progressive disease prior to completion of cycle 3, patient refusal, and no anatomic response recorded.</population>
        <group_list>
          <group group_id="O1">
            <title>Dacarbazine</title>
            <description>Dacarbazine 850 mg/m^2 IV Day 1 of each 21 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlate the Time to Progression With Best Anatomic Response</title>
          <description>-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
          <population>29 patients were not evaluable due to various reasons such as toxicity, progressive disease prior to completion of cycle 3, patient refusal, and no anatomic response recorded.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="9.41">The median and upper confidence level were not estimable due to the limited number of events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.14" lower_limit="3.91" upper_limit="6.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" lower_limit="1.84" upper_limit="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlate Time to Progression With Best Metabolic Response</title>
        <description>-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
        <time_frame>Completion of follow-up (estimated to be 1 year)</time_frame>
        <population>31 patients were not evaluable due to various reasons such as toxicity, progressive disease prior to completion of cycle 3, patient refusal, and no target lesions on PET scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Dacarbazine</title>
            <description>Dacarbazine 850 mg/m^2 IV Day 1 of each 21 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlate Time to Progression With Best Metabolic Response</title>
          <description>-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
          <population>31 patients were not evaluable due to various reasons such as toxicity, progressive disease prior to completion of cycle 3, patient refusal, and no target lesions on PET scan.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Partial metabolic response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.95" lower_limit="1.61">The upper confidence level was not estimable due to the limited number of events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable metabolic disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.30" lower_limit="2.53" upper_limit="9.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive metabolic disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" lower_limit="1.84" upper_limit="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlate Overall Survival With Best Anatomic Response</title>
        <time_frame>Completion of follow-up (estimated to be 1 year)</time_frame>
        <population>26 patients were not evaluable for this outcome measure for various reasons including unknown survival status, progressive disease prior to cycle 3, no anatomic response noted, and toxicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Dacarbazine</title>
            <description>Dacarbazine 850 mg/m^2 IV Day 1 of each 21 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlate Overall Survival With Best Anatomic Response</title>
          <population>26 patients were not evaluable for this outcome measure for various reasons including unknown survival status, progressive disease prior to cycle 3, no anatomic response noted, and toxicity.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.16">The lower and upper confidence levels were not estimable due to the limited number of events. Only two patients had partial response and only one of them died within the time frame of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.77" lower_limit="8.75" upper_limit="23.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.96" lower_limit="5.72" upper_limit="10.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlate Overall Survival With Best Metabolic Response</title>
        <time_frame>Completion of follow-up (estimated to be 1 year)</time_frame>
        <population>28 patients were not evaluable for this outcome measure due to various reason such as progressive disease prior to cycle 3, unknown survival status, no target lesion on PET scan, and toxicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Dacarbazine</title>
            <description>Dacarbazine 850 mg/m^2 IV Day 1 of each 21 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlate Overall Survival With Best Metabolic Response</title>
          <population>28 patients were not evaluable for this outcome measure due to various reason such as progressive disease prior to cycle 3, unknown survival status, no target lesion on PET scan, and toxicity.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Partial metabolic response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.16" lower_limit="7.3" upper_limit="25.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable metabolic disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.59" lower_limit="6.91" upper_limit="44.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive metabolic disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.75" lower_limit="6.05" upper_limit="12.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dacarbazine</title>
          <description>Dacarbazine 850 mg/m^2 IV Day 1 of each 21 day cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Abdominal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy - motor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Lung hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Brachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Anisocoria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Floaters</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abodominal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Dyspepsia/heartburn</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Esophageal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>GI abdominal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Reflux gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Taste alterations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Ulcer: GI duodenum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Cold sore</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Face pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Flu like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Swelling - face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Boil</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Neutropenic fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Thrush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Elevated PTT</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Elevated troponin I</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>INR</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Leukocytes (WBC)</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Neutrophils (ANC)</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>SGOT (AST)</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>SGPT (ALT)</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Albumin - low</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Calcium - high</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Calcium - low</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Glucose - high</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Glucose - low</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Phosphorus - low</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Potassium - high</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Potassium - low</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Sodium - high</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Sodium - low</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Contracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Extremity pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Intraspinal hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Shoulder/back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Disease pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Neuropathy (sensory)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Speech impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Mood alteration - agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Mood alteration - anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Frothy urine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Urine color change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Bronchospasm: wheezing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Nose hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pnemonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pulmonary hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Voice changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acneiform rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Diaphoresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Photosensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Inferior vena cava thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brian Van Tine, M.D., Ph.D.</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-362-5817</phone>
      <email>bvantine@dom.wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

